# A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults

> **NCT02390609** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Ibrutinib (Treatment A) [Reference]
- **DRUG:** Ibrutinib (Treatment B)
- **DRUG:** Ibrutinib (Treatment C)
- **DRUG:** Ibrutinib (Treatment D)
- **DRUG:** Ibrutinib (Treatment E)
- **DRUG:** Ibrutinib (Treatment F)

## Key facts

- **NCT ID:** NCT02390609
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2015-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02390609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02390609, "A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02390609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*